[SCHEDULE 13D/A] Arcus Biosciences, Inc. SEC Filing

Rhea-AI Filing Summary

Gilead Sciences filed Amendment No. 6 to its Schedule 13D on Arcus Biosciences, updating its beneficial ownership and voting power disclosures. Gilead reports beneficial ownership of 31,424,760 shares of Arcus common stock, representing 25.6% of the class. Gilead has sole voting and dispositive power over the same 31,424,760 shares and no shared power.

The percentage is based on 122,856,086 shares outstanding as reported in a prospectus supplement dated October 31, 2025. The filing details prior purchases under multiple purchase agreements and offerings. It also notes that Jeffrey A. Bluestone holds options exercisable within 60 days for 10,750 shares, equating to 0.01% on an as‑converted basis.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 6)

Arcus Biosciences, Inc.

(Name of Issuer)

Common Stock, par value $0.0001

(Title of Class of Securities)

03969F109

(CUSIP Number)

Gilead Sciences, Inc.
333 Lakeside Drive,
Foster City, CA, 94404
650-574-3000

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

11/03/2025

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No. 03969F109

1

Name of reporting person

GILEAD SCIENCES, INC.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 31,424,760.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 31,424,760.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

31,424,760.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

25.6 %

14

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person:

The number of shares reported in rows 7, 9, and 11 consists of (i) 2,200,000 shares of the common stock, par value $0.0001 per share (the "Common Stock"), of Arcus Biosciences, Inc. (the "Issuer") purchased in the 2020 Public Offering, (ii) the initial purchase of 5,963,029 shares of Common Stock pursuant to the Purchase Agreement, (iii) the subsequent purchase of 5,650,000 shares of Common Stock pursuant to the Amended and Restated Purchase Agreement, (iv) the subsequent purchase of 1,010,000 shares of Common Stock pursuant to the Second Amended and Restated Purchase Agreement, (v) the subsequent purchase of 15,238,095 shares of Common Stock of the Issuer pursuant to the Third Amended and Restated Purchase Agreement, and (vi) the subsequent purchase of 1,363,636 shares of Common Stock pursuant to the Public Offering. The percent reported in row 13 is calculated based upon 122,856,086 shares of Common Stock issued and outstanding, as reported in the prospectus supplement filed by the Issuer with the Securities and Exchange Commission (the "SEC") on October 31, 2025.

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock, par value $0.0001
(b)	Name of Issuer: Arcus Biosciences, Inc.
(c)	Address of Issuer's Principal Executive Offices: 3928 Point Eden Way, Hayward, CALIFORNIA , 94545.
Item 1 Comment: This Amendment No. 6 (the "Amendment") amends the initial Schedule 13D filed by the Reporting Person on July 17, 2020, as amended by Amendment No. 1 to Schedule 13D filed with the SEC by the Reporting Person on February 2, 2021, Amendment No. 2 to Schedule 13D filed with the SEC by the Reporting Person on July 6, 2023, Amendment No. 3 to Schedule 13D filed with the SEC by the Reporting Person on January 31, 2024, Amendment No. 4 to Schedule 13D filed with the SEC by the Reporting Person on March 5, 2025 and Amendment No. 5 to Schedule 13D filed with the SEC by the Reporting Person on July 15, 2025 (the "Original Schedule 13D," and as amended by Amendment No. 6, the "Schedule 13D"). Capitalized terms used but not defined in this Amendment shall have the same meanings ascribed to them in the Original Schedule 13D.
Item 5.	Interest in Securities of the Issuer
(a)	Item 5(a) of the Schedule 13D is hereby amended and restated to read as follows: Number of shares of Common Stock beneficially owned: Gilead - 31,424,760 shares Jeffrey A. Bluestone - 10,750 shares Percent of class: Gilead - 25.6% Jeffrey A. Bluestone - 0.01% The number of shares of Common Stock beneficially owned by Gilead consists of (i) 2,200,000 shares of Common Stock purchased in the 2020 Public Offering, (ii) the initial purchase of 5,963,029 shares of Common Stock pursuant to the Purchase Agreement, (iii) the subsequent purchase of 5,650,000 shares of Common Stock pursuant to the Amended and Restated Purchase Agreement, (iv) the subsequent purchase of 1,010,000 shares of Common Stock pursuant to the Second Amended and Restated Purchase Agreement, (v) the subsequent purchase of 15,238,095 shares of Common Stock pursuant to the Third Amended and Restated Purchase Agreement, and (vi) the subsequent purchase of 1,363,636 shares of Common Stock pursuant to the Public Offering. The number of shares of Common Stock beneficially owned by Mr. Bluestone consists of options to purchase 10,750 shares of Common Stock exercisable within 60 days. The percentage ownership for Gilead was calculated based upon 122,856,086 shares of common stock of the Issuer issued and outstanding, as reported in the prospectus supplement filed by the Issuer with the SEC on October 31, 2025. The percentage ownership for Mr. Bluestone was calculated based upon 122,866,836 shares of Common Stock issued and outstanding, based on 122,856,086 shares of Common Stock issued and outstanding and assuming the immediate exercise in full by Mr. Bluestone of his options. To the best knowledge of the Reporting Person, none of the individuals listed on Schedule I beneficially owns any of the Issuer's Common Stock, except Mr. Bluestone, who has received options to purchase shares of Common Stock in partial payment for his service on the Issuer's Scientific Advisory Board.
(b)	Item 5(b) of the Schedule 13D is hereby amended and restated to read as follows: Number of shares as to which such person has: (i) Sole power to vote or to direct the vote: Gilead - 31,424,760 shares Jeffrey A. Bluestone - 10,750 shares (ii) Shared power to vote or to direct the vote: Gilead - 0 shares Jeffrey A. Bluestone - 0 shares (iii) Sole power to dispose or to direct the disposition of: Gilead - 31,424,760 shares Jeffrey A. Bluestone - 10,750 shares (iv) Shared power to dispose or to direct the disposition of: Gilead - 0 shares Jeffrey A. Bluestone - 0 shares

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

GILEAD SCIENCES, INC.

Signature:	/s/ Andrew D. Dickinson
Name/Title:	Andrew D. Dickinson, Executive Vice President and Chief Financial Officer
Date:	11/05/2025